Zai Lab, a two-year old Shanghai biotech, has in-licensed global rights from UCB, the Belgium multinational, to a first-in-class monoclonal antibody aimed at treating autoimmune and other inflammatory diseases. According to Zai, the candidate is ready for IND enabling studies and will probably start a clinical Phase I trial in 2016. The initial indications appear to be graft-versus-host disease and inflammatory bowel disease. So far, Zai has in-licensed four molecules, all of them close to clinical stage.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
